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Abstract
Background: Previous research has shown that academic physicians conflicted by funding from the pharmaceutical industry
have corrupted evidence based medicine and helped enlarge the market for drugs. Physicians made pharmaceutical-
friendly statements, engaged in disease mongering, and signed biased review articles ghost-authored by corporate
employees. This paper tested the hypothesis that bias affects review articles regarding rimonabant, an anti-obesity drug
that blocks the central cannabinoid receptor.
Methods/Principal Findings: A MEDLINE search was performed for rimonabant review articles, limited to articles authored
by USA physicians who served as consultants for the company that manufactures rimonabant. Extracted articles were
examined for industry-friendly bias, identified by three methods: analysis with a validated instrument for monitoring bias in
continuing medical education (CME); analysis for bias defined as statements that ran contrary to external evidence; and a
tally of misrepresentations about the endocannabinoid system. Eight review articles were identified, but only three
disclosed authors’ financial conflicts of interest, despite easily accessible information to the contrary. The Takhar CME bias
instrument demonstrated statistically significant bias in all the review articles. Biased statements that were nearly identical
reappeared in the articles, including disease mongering, exaggerating rimonabant’s efficacy and safety, lack of criticisms
regarding rimonabant clinical trials, and speculations about surrogate markers stated as facts. Distinctive and identical
misrepresentations regarding the endocannabinoid system also reappeared in articles by different authors.
Conclusions: The findings are characteristic of bias that arises from financial conflicts of interest, and suggestive of
ghostwriting by a common author. Resolutions for this scenario are proposed.
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Introduction
The epidemic of obesity began, as many modern epidemics do,
with a reclassification. In 1998, the number of overweight and
obese individuals in the USA swelled instantaneously by 37
million, when a NIH task force redefined overweight as a body
mass index (BMI) $25 kg/m
2, and obesity as BMI $30 [1]. The
task force was criticized for ignoring studies that disputed BMI as a
valid surrogate marker for adiposity, and for circuitously basing its
reclassification upon opinions and flawed studies authored by its
own members, rather than independent studies [2,3]. Nearly 90%
of the obesity task force members had financial ties to the weight-
loss industry, including pharmaceutical companies and weight loss
clinics [4]. The Chair of the task force stated that pharmaceutical
corporations ‘‘have no influence over what I say. … I’m not
accepting payment directly. It comes through a company that runs
continuing education. Maybe that’s a bad thing. But if you did
away with this, you would wipe out 80 percent of the medical
education programs’’ [4]. The Chair of the task force was former
President of the NAASO (North American Association for the
Study of Obesity, also called the Obesity Society). The NAASO is
an accredited continuing medical education (CME) provider. The
ex-President approved NAASO CME programs as free of
commercial bias [5,6], although the programs were funded by
Sanofi-Aventis (the manufacturer of a weight-loss drug), and he
received financial support from Sanofi-Aventis [7]. A year after
chairing the obesity task force, the ex-President was identified in a
lawsuit as the guest author of a ghostwritten review on obesity
commissioned by Wyeth-Ayerst regarding long-term, off-label use
of ‘‘fen-phen’’ (fenfluramine and phentermine) [8].
In 2004, researchers from the Centers for Disease Control
(CDC) reported that obesity caused 400,000 deaths in the year
2000 [9]. Despite the fact that this statistic was unsupportable (and
was downsized after a congressional inquiry [10]), Medicare
officials promptly announced they would treat obesity as a disease,
opening the way for government reimbursement of treatments
[11]. A second group of researchers reanalyzed the data used to
generate the 400,000 number. After adjusting for confounding
factors, obesity-related deaths in 2000 numbered 25,814 – less
than 7% of the original estimate [12]. U.S. Surgeon General
Richard Carmona subsequently announced, ‘‘Obesity is the terror
within…the magnitude of the dilemma will dwarf 9–11 or any
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health hazard, and its prevalence is rising. But the framing of
obesity as a 9–11 terror is an example of disease mongering, which
includes the promotion of new diseases, the expansion of illness
boundaries, the medicalization of normal physiology, and the
expansion of markets for disease treatments [14].
Cannabinoids, evidence based medicine, and surrogate
markers
Two new anti-obesity drugs, rimonabant (AcompliaH, Sanofi-
Aventis) and taranabant (Merck), work by a new mechanism:
blockade of the cannabinoid 1 (CB1) receptor, an integral part of
the endocannabinoid system (ECS) [15]. Obesity leads to excessive
endocannabinoid production, which drives CB1 in a feed-forward
dysfunction [16]. Endocannabinoids as well as plant cannabinoids
in marijuana stimulate appetite, so it makes sense that a CB1
antagonist would suppress appetite. However, endocannabinoids
do more than modulate appetite. The ECS plays important roles
in neurogenesis, neurodegenerative diseases, mood disorders, pain
perception, gut function, immunity, and inflammation [17]. These
important roles suggest that ECS blockade might cause adverse
effects. However, this type of physiological rationale is not
accepted by evidence based medicine (EBM) guidelines [18].
EBM accepts randomized clinical trials (RCTs) as best evidence.
Pharmaceutical corporations increasingly recognize the value of
RCTs in shaping EBM. They treat RCTs as important resources
to be managed, thereby extending their marketing arm into the
peer-reviewed medical literature [19]. Pharmaceutical corpora-
tions spent US$57.5 billion on marketing alone in 2004. This was
substantially greater than US$31.5 billion expended on domestic
pharmaceutical research [20].
Four rimonabant-in-obesity (RIO) RCTs, all funded and
conducted by Sanofi-Aventis, have been published, although 25
RCTs of rimonabant for the treatment of obesity and diabetes are
completed or underway [21]. This 4-to-25 ratio suggests
‘‘publication bias,’’ which arises when pharmaceutical corpora-
tions choose not to publish unfavorable studies [22,23]. Criticisms
of the RIO trials included the use of unvalidated or disputed
surrogate endpoints [24,25], favorable claims not supported by
trial data [26], overstated treatment efficacy [27], downplayed
adverse effects [25,28,29], lack of internal validity and external
validity or generalizability [30,31], and failure to disclose
financially-conflicted interests [32]. However, these criticisms
and other types of narrative reviews are not recognized by
EBM; EBM relies upon meta-analyses of RCTs [18]. A meta-
analysis of the RIO RCTs concluded that rimonabant was safe
and effective [33]. The meta-analysis was funded by Sanofi-
Aventis. Industry-funded meta-analyses tend to be less transparent,
have more methodological flaws, and make more pro-industry
conclusions regarding drugs than do independent meta-analyses
[34]. Consistent with this, four independent meta-analyses of the
RIO trials have questioned rimonabant’s efficacy and potential for
adverse effects [26,35–37].
One taranabant clinical trial has been published in the peer-
reviewed literature [38]. The study also used unvalidated or
disputed surrogate endpoints, made claims not supported by trial
data, and downplayed adverse effects. The use of surrogate
endpoints instead of clinical end points has come under recent
scrutiny. Surrogate markers help get drugs to the market quickly,
but they may not correlate with disease outcome. Just because
patients with flu have a fever, for example, doesn’t mean that
treating the fever will clear the infection [39]. Rosiglitazone was
fast-tracked through FDA approval because it lowered serum
glucose levels, but a meta-analysis showed that rosiglitazone
increased the risk of myocardial infarction [40]. According to
Steven Nissen, author of the meta-analysis, ‘‘Wait long enough,
and you’re going to find that all surrogates eventually fail due to
these off-target effects’’ [39]. Serum cholesterol serves as a
surrogate for cardiovascular disease, and ezetimibe-simvastatin
lowers serum cholesterol, but ezetimibe-simvastatin did not slow
the development of atherosclerosis in patients [41]. Rimonabant
and taranabant RCTs employed several disputed surrogate
markers. Even ‘‘metabolic syndrome,’’ a composite surrogate
measure, has limited value as a cardiovascular risk marker [42,43].
Sanofi-Aventis answered these criticisms with the STRADIVARIUS
study, which measured rimonabant’s effects upon coronary artery
atheroma volume [44]. The study was conducted by Steve Nissen,
a champion of clinically-relevant outcome measures [39,40,45].
Coronary artery atheroma volume, however, is a nonvalidated
surrogate endpoint for cardiovascular outcomes [46,47]. The
study showed that rimonabant had no effect on percent atheroma
volume, although Nissen and colleagues noted improvements in
secondary nonvalidated surrogate endpoints, such as normalized
total atheroma volume [44].
ECB, CME, and review articles
In addition to RCTs and meta-analyses, clinicians base rational
EBM decisions upon CME presented by fellow physicians.
Clinicians must participate in CME to fulfill licensure require-
ments, making them a ‘‘captured audience’’ for corporate-
sponsored messages. Pharmaceutical corporations routinely seed
CME with review articles that promote their products, thereby
further unraveling EBM [48]. Review articles often contain
industry bias [49,50], especially articles in journal supplements,
which are not usually peer reviewed [19]. Journal supplements are
quite lucrative to medical journals, because pharmaceutical
corporations sponsor them. Corporate employees may ghostwrite
review articles, and then influential physicians are recruited to sign
the articles [51]. Whereas authorship establishes accountability
and responsibility, ghost authorship increases the potential for
conflicted manipulation. Documents made public in litigation
showed that Wyeth-Ayerst [8], Pfizer [52,53], and Merck [54]
employed corporate authors to ghost author CME review articles.
In the past few years, several CME review articles of
rimonabant have been published. Some authors of the review
articles also served on the NIH obesity task force, the NAASO
board, and coauthored RIO publications. One rimonabant review
article was presumably ghostwritten because the authors were
listed as ‘‘editors,’’ without identifying a primary author, and a
Sanofi-Aventis copyright appeared in small print on the back
cover of the supplement [55]. The purpose of this paper was to test
the hypothesis that rimonabant review articles expressed a high
incidence of bias.
Methods
Review articles were identified through a MEDLINE search
using the keywords endocannabinoid AND obesity AND rimona-
bant, limited to articles published prior to 2007 (when the FDA
reviewed rimonabant). To be included in the analysis, a review
article had to meet the following criteria:
a. ample information ($2 paragraphs) describing the ECS
system and obesity;
b. ample information ($1 paragraph) describing obesity and
rimonabant;
c. authored by a USA physician who received financial support
from Sanofi-Aventis.
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authors, only one article by each author was analyzed; the earliest
published article was analyzed and subsequent publications were
excluded. Evidence of real or potential conflicts of interest (i.e.,
financial support in the form of honoraria, education support,
research funding, or identification as a consultant or speaker) was
obtained by searching Google using each physician’s name
combined with Sanofi-Aventis. Biases and misrepresentations
were measured by three methods:
a. Review articles were analyzed with a validated instrument for
monitoring bias in CME [56]. The Takhar instrument
consisted of 13 questions (see Table 1), with scores graded
on a scale from 1 (strongly disagree this paper displays bias) to
4 (strongly agree this paper displays bias), or N/A (not
applicable). The instrument was designed for oral CME
presentations, so it was slightly modified (e.g., ‘‘author’’
instead of ‘‘speaker’’).
b. The ‘‘RIO bias tally’’ searched articles for biased statements
or inappropriate omissions that originally appeared in the
RIO publications (see Table 2), graded on a scale from 0 (no
bias evident in review article), 1 (a mix of biased and unbiased
statements) to 2 (bias evident), or N/A (no statement made
regarding the item).
c. Articles were scanned for recurrent themes and for identical
misrepresentations about the ECS written by different
authors.
Results
Eight review articles were identified that met inclusion criteria
[57–64]. Only three of eight articles disclosed authors’ conflicts of
interest with Sanofi-Aventis. Two articles carried the statement
that the author had ‘‘no conflict of interest,’’ despite easily accessible
information to the contrary—searches with Google revealed all the
authors served as consultants, or on speaker bureaus, or received
other financial support from Sanofi-Aventis.
The Takhar CME bias instrument demonstrated bias in all the
review articles (Table 3), with mean scores ranging from 2.6
(weakly biased) to 3.6 (strongly biased). Collectively, the mean
Takhar score was 3.08 (95% CI: 2.78 to 3.39). Ten industry-
friendly statements that originally appeared in RIO publications
reappeared in the eight review articles (Table 3). Biased statements
included disease mongering, speculations regarding surrogate
markers stated as facts, lack of acknowledgment of RIO design
flaws, and exaggerated statements of rimonabant’s efficacy and
safety. Mean scores from the Takhar bias instrument (Table 3)
correlated with mean scores from the RIO bias tally (Table 3), but
fell short of statistical significance (r=0.50, p=0.11).
Recurrent visual and textual themes emerged from the eight
review articles. Graphics from Sanofi-Aventis promotional mate-
rials [55] reappeared in a review article [61]. Articles by different
authors in different journals nevertheless used similar stock photos
from Getty Images, Inc. (e.g., [60] and [63]). Three unusual yet
identical misrepresentations about the ECS appeared in articles by
different authors:
1. The hypothalamus was named first in descriptions of
CB1 expression in the brain. Three of eight articles shared
this misrepresentation [57,58,63]. Actually CB1 expression is
relatively low in the hypothalamus. In human brain, the rank
order of CB1 receptor density is: substantia nigra.globus
pallidus.hippocampus.cerebral cortex.putamen.cauda-
te.cerebellum.amygdala.thalamus=hypothalamus [65].
This error may arise from the fact that Sanofi-sponsored
research has focused upon the hypothalamus (e.g., [66]).
2. Adipose tissue was listed amongst tissues with dense
CB1 expression. Six of eight articles stated this [57–61,63].
Sanofi-sponsored research has highlighted adipose tissue in
rimonabant’s ‘‘peripheral effects’’ (e.g., [67]). However, most
independent studies have found that CB1 expression is
relatively low or undetectable in adipose and adipocyte-rich
tissue such as bone marrow [68–71]. Adipocyte CB1 expression
actually decreases in obese research participants [67,72].
Table 1. Thirteen questions (A to M) comprising the Takhar instrument [56] for monitoring bias in Continuing Medical Education
(with adaptations applied to rimonabant review articles in italics)
A. Conflict of interest was not declared by the author with a disclosure statement.
B. Commercial interest was clearly present (via the Sanofi name or company logo, product branding, illustrations reproduced or adapted from Sanofi publications,
or reference to a medical education and communication company).
C. Valid, credible evaluation of peer-reviewed evidence-based medicine (EBM) was not used in the presentation, based on my perception.
D. The author did not integrate his or her clinical expertise with the best available EBM in his/her presentation.
E. The data were presented in an unbalanced manner, and some outcomes were favored over others (i.e., data were presented that favored one company’s
products over another’s).
F. Published sources were identified for evidence reported.
G. The data presented in the program were incomplete or framed in a biased fashion.
H. Rival drugs for treatment of obesity were not mentioned (e.g., orlistat and sibutramine, or if mentioned, their adverse affects were emphasized over their
efficacy).
I. Trade names of the drug were used (Acomplia or rimonabant, named after the Sanofi lead researcher, RInaldi-Carmona), rather than generic names (SR141716
or SR141716A).
J. If unapproved uses of drugs were discussed, the author informed the audience of this according to current guidelines.
K. The paper does not contribute to the best interests of patients.
L. The paper promotes marketing of drug knowledge.
M. This program enhances medical knowledge.
doi:10.1371/journal.pone.0005092.t001
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articles (with evidence contrary in italics)
1. Disease mongering: the ECS requires pharmacological blockade because it induces detrimental effects: overfeeding, obesity, diabetes, hyperlipidemia, and/or
hepatic steatosis. Review articles did not mention the many beneficial effects of the ECS, which include anti-inflammatory and analgesic effects,
immunomodulatory and neuroprotective effects, and beneficial mood-altering effects [17].
2. Weight reduction from rimonabant was described as ‘‘appreciable,’’ ’’large,’’ ‘‘dramatic,’’ etc. Weight loss was modest: less than 5% of total body weight. Trial
participants with a mean weight of 99.6 kg (219 lb) on the highest dose of rimonabant lost 4.7 kg (10.4 lb) compared to placebo [26,35–37]. Participants re-
randomized to placebo regained most of their weight.
3. Rimonabant’s reduction of high-density lipoprotein (HDL) cholesterol was highlighted, while no mention was made of its inability to lower total cholesterol or
LDL. Rimonabant produced a statistically significant—but clinically marginal—3.5 mg/dl increase in HDL. No improvements were seen in total cholesterolo rL D L
cholesterol [26,35–37].
4. Adverse effects were not mentioned or were described as ‘‘mild,’’ ‘‘transient,’’ ‘‘well tolerated,’’ or ‘‘slightly greater than placebo.’’ Rimonabant caused
significantly more adverse events than did placebo; trial participants given rimonabant were 2.5 times more likely to discontinue the treatment because of
depressive mood disorders than were those given placebo [37].
5. The external validity (or generalizability) of the RIO trials went unquestioned. Potential trial participants with depression were excluded from RIO trials; in actual
clinical practice about half of patients seeking treatment are depressed [30,37].
6. Methodological weaknesses (internal validity) in RIO trials went unmentioned; or if high drop-out rates were mentioned, they were justified as ‘‘typical of
obesity trials.’’ The authors of two RIO trials did not report appropriate methods of randomization or allocation concealment, and none provided details regarding
blinding of participants or treatment providers [35]. High dropout rates and nonadherence in all RIO trials may have resulted in overestimation of the benefits of
treatment [29].
7. Relative contraindications other than depression were not mentioned. The rimonabant package insert advises against taking rimonabant when breast-feeding or
pregnant, advises ‘‘special care’’ in patients with impaired liver or renal function, epilepsy, or who are under 18 years of age, and warns against co-administration
with cytochrome P-450 CYP3A4-modulating drugs [87,88].
8. Inappropriate surrogate markers went unquestioned. BMI of $25 was used as a surrogate marker for adiposity and an accurate predictor of mortality. BMI is
not a good proxy for adiposity; BMI fails to account for age, gender, ethnicity, fat distribution, physical conditioning, and disease state [3]. Mortality may not
increase significantly until BMI .35, and mortality may actually be lowest in the BMI 25–30 range [12,89].
9. Competing drugs were not mentioned or mentioned only in a way that highlighted adverse effects. No evidence supports the superiority of rimonabant to
orlistat and sibutramine: no head-to-head comparisons have been done.
10. No mention was made of rimonabant potentially counteracting drugs or other therapeutic interventions that augment the ECS. Endocannabinoid tone or CB1
expression are enhanced by paracetamol (acetaminophen), nonsteroidal anti-inflammatory drugs, tricyclic antidepressants, diazepam, dexamethasone, and
docosahexaenoic acid (fish oil) supplements, as well as aerobic exercise, spinal manipulation, massage, and perhaps acupuncture [15].
doi:10.1371/journal.pone.0005092.t002
Table 3. Bias in eight rimonabant review articles.
1
Takhar
bias
scale item Eight review articles (citation numbers from Reference section)
RIO bias
tally item
[57] [58] [59] [60] [61] [62] [63] [64]
A 4/1 3/2 4/2 1/2 4/2 4/2 4/2 1/2 1
B 3/2 3/2 3/2 4/2 3/2 3/2 4/2 4/2 2
C 3/N / A 3/2 3/2 3/2 3/2 3/0 3/2 3/2 3
D 3/2 2/1 3/1 4/2 2/0 1/1 4/0 3/1 4
E 4/2 2/2 3/2 4/2 3/2 2/2 4/2 3/2 5
F 2/2 2/2 2/2 3/2 2/2 2/2 2/2 2/2 6
G 4/2 3/2 3/2 4/2 4/2 4/2 4/2 4/2 7
H 4/1 2/2 2/2 4/2 4/2 2/2 4/2 3/2 8
I 3/2 3/1 3/0 3/2 3/2 3/0 3/2 3/1 9
J N/A N/A N/A N/A N/A N/A N/A N/A 10
/2 /2 /2 /2 /2 /2 /2 /2
K 22232 232
L 23443 444
M 23343 343
Takhar mean 3.0 2.6 2.9 3.4 3.0 2.8 3.6 2.9
1.78 1.8 1.7 2.0 1.8 1.5 1.8 1.8 RIO bias mean
1Each article was scored with the Takhar bias instrument (items A to M in the first column, see Methods and Table 1), followed by a back-slash (/), and then scored with
the RIO bias tally (items 1 to 10 in the last column, see Methods and Table 2)
doi:10.1371/journal.pone.0005092.t003
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CB1 expression. Five of eight articles stated this [57,59–
61,63]. Sanofi-sponsored researchers claim that hepatocytes
contribute to rimonabant’s peripheral effects in mice [73]. On
the other hand, CB1 expression is sufficiently low that some
independent studies failed to identify CB1 in liver at all [68,70].
Recent studies have detected CB1 in fibrotic liver cells; hepatic
CB1 expression in humans may be limited to cirrhotic or other
pathological conditions [74].
Discussion
All the authors of rimonabant review articles held academic
positions, many at prestigious institutions. They typified ‘‘medical
opinion leaders’’ sought by pharmaceutical corporations to sign
ghostwritten articles [48,52,53,75]. Seven of eight rimonabant
review articles appeared in journal supplements, which are non-
peer-reviewed, usually industry-funded publications known to
carry a high incidence of bias [19]. The Takhar bias instrument
demonstrated bias in all eight articles (Table 3). The mean score
was 3.08 (95% CI: 2.78 to 3.39), significantly greater than the 2.5
score that separates unbiased from biased publications [56]. In
comparison, the mean score for 17 accredited CME events
evaluated by Takhar and colleagues was 1.65 (95% CI: 1.32 to
1.99) [56]. An additional analysis of non-Sanofi-supported review
articles would provide compelling data for comparison. But
‘‘absence of evidence is not evidence of absence’’—to prove lack
of Sanofi support would require much more than a Google search.
The RIO bias tally identified ten nearly-identical industry-
friendly statements or inappropriate omissions in articles written
by different authors (Table 3). These statements originally
appeared in RIO publications, which acknowledged editorial
assistance by Sanofi-Aventis (e.g., [7]), whereas the review articles
did not. Nearly identical illustrations reappeared in several articles,
and distinctive factual misrepresentations reappeared in articles by
different authors. Replication of passages in a single author’s work
may indicate only carelessness, but replication of passages in
articles by different authors raises the question of whether a
common ghost author was involved. One rimonabant review
article (not included in the analysis because we found no evidence
that Sanofi funded its authors) listed the authors as ‘‘editors,’’ and
the primary (ghost-) author was unidentified [55]. Of course,
judgment regarding ghostwriting or plagiarism should be withheld
until the candidate publications are appraised by an editorial
board or ethics committee. The same proviso was made by Errami
and Garner [76], who used a computational text-searching
algorithm to identify ‘‘duplicate publications’’ and ‘‘plagiarism’’
in abstracts cited by PubMed. A search of their database (http://
spore.swmed.edu/dejavu/) using the keyword ‘‘rimonabant’’
revealed seven pairs of duplicate publications (including one
review article identified herein). The cases of suspected plagiarism
repeatedly engaged in disease mongering, which expands the
market for those who sell disease remedies. Disease mongering and
‘‘supersizing’’ of rimonabant’s indications have been criticized
[43], and satirized by a description of ‘‘indolebant,’’ a fictional
CB1 antagonist that treats ‘‘extreme laziness’’ [77].
Rationally choosing the best medication, like other sorts of
clinical decision-making, has increasingly relied upon EBM. Thus
whoever generates EBM, by funding RCTs, meta-analyses, and
CME, may bias clinical decision-making regarding pharmaceuti-
cals [78]. Industry-friendly bias is not unique to rimonabant
publications. The discovery process in recent litigation has
revealed that many pharmaceutical corporations recruit and train
influential physicians for the purpose of manipulating their
colleagues. These physicians sign biased ghostwritten articles
without disclosing conflicts of interest [48,52,53,75]. For partici-
pating in Parke-Davis promotional CME efforts, physicians
received honoraria up to US$158,250, in addition to paid travel,
lodging, and amenities at luxury resorts [53]. This behavior is not
limited to MDs — a pharmaceutical marketing disclosure law in
Vermont revealed that the third highest recipient in the state was
an osteopathic physician who received $99,843 in 2007 [79].
Despite the fact that osteopathy began as an essentially drug-free
school of medicine, the pharmaceutical industry now imparts
significant financial leverage over that profession.
Financial conflicts of interest also bias clinical practice
guidelines and FDA decisions. An analysis of 44 clinical guidelines
revealed 87% of panelists received financial support from
pharmaceutical companies, yet only two of the guidelines disclosed
panelists’ financial conflicts [80]. A larger investigation of over 200
guidelines revealed about 70% of guideline panels being affected
[81]. In one guideline panel, every panel member was paid by a
drug manufacturer, and that manufacturer’s drug was recom-
mended by the panel [81]. Members of FDA drug advisory
committees have financial conflicts but rarely recluse themselves
from voting, and they tend to vote in favor of corporations that
sponsored them [82]. Ten of the 32 FDA panelists that voted in
favor of rofecoxib and valdecoxib received fees from the makers of
those drugs [83]. Had those financially conflicted panelists been
reclused, the FDA would have voted against continued sales of
rofecoxib and valdecoxib [83].
In summary, financial conflicts permeate the system and are by
no means limited to corporations referenced in this article, such as
Merck, Parke-Davis, Pfizer, Sanofi-Aventis, and Wyeth-Ayerst.
On balance, pharmaceutical corporations do good work and aid in
humanitarian efforts. For example Sanofi-Aventis provides
artemisinin at cost to malaria-endemic countries [84]. Neverthe-
less, ghost authorship and the corrupting effects of covert financial
support must cease. Only three of eight rimonabant review articles
disclosed corporate sponsorship; two authors specifically denied
conflicts. Lack of disclosure prevents readers from judging the
credibility of an author. Medical journals should require stronger
author disclosure procedures, and universities should discipline
academics who sign ghostwritten articles. This behavior should be
regarded as unethical misconduct [85]. More broadly, researchers
with conflicts of interest should not be allowed to sit on guideline
committees and regulatory boards. Corporate funding of CME
programs and review articles should be abolished.
Post script
While this paper was under review, Merck halted taranabant
RCTs, and Sanofi-Aventis removed rimonabant from the
European market. The FDA rejected rimonabant after data
submitted by Sanofi-Aventis revealed adverse effects in RIO trials
that went unreported in RIO publications [86], including one
death in a rimonabant-treated subject (ruled a suicide by the FDA,
[86]) that did not appear in the pertinent publication [7]. Although
the risk-benefit ratio of cannabinoid receptor blockade may
preclude its use for chronic conditions such as obesity and drug or
alcohol dependence, cannabinoid receptor blockade could serve in
the treatment of acute endocannabinoid dysregulation, such as
hepatic cirrhosis, hemorrhagic or endotoxic shock, cardiac
reperfusion injury, and doxorubicin-induced cardiotoxicity [15].
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